Creative Planning Grows Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Creative Planning increased its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 58.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,193 shares of the medical instruments supplier’s stock after acquiring an additional 2,287 shares during the quarter. Creative Planning’s holdings in ICU Medical were worth $1,128,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Silvercrest Asset Management Group LLC increased its stake in shares of ICU Medical by 109.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after purchasing an additional 145,485 shares in the last quarter. Mesirow Institutional Investment Management Inc. bought a new position in ICU Medical during the 1st quarter valued at approximately $15,425,000. Victory Capital Management Inc. increased its position in ICU Medical by 2,966.3% during the 2nd quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock valued at $16,844,000 after buying an additional 137,222 shares in the last quarter. Millennium Management LLC raised its stake in ICU Medical by 327.8% during the second quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock valued at $16,158,000 after buying an additional 104,264 shares during the last quarter. Finally, Granite Investment Partners LLC bought a new stake in ICU Medical in the second quarter worth $10,650,000. 96.10% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ICUI. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Thursday, October 10th. KeyCorp lifted their target price on shares of ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Jefferies Financial Group initiated coverage on shares of ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price target on the stock. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Finally, Raymond James upped their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.25.

ICU Medical Stock Performance

Shares of NASDAQ ICUI opened at $170.73 on Friday. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76. The firm’s 50-day moving average price is $173.70 and its 200-day moving average price is $136.46. ICU Medical, Inc. has a 52-week low of $78.28 and a 52-week high of $188.53. The company has a market cap of $4.17 billion, a PE ratio of -58.47 and a beta of 0.66.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.56. The company had revenue of $596.50 million for the quarter, compared to analysts’ expectations of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the company posted $1.58 earnings per share. As a group, analysts anticipate that ICU Medical, Inc. will post 3.81 EPS for the current year.

Insider Buying and Selling

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the transaction, the vice president now owns 4,482 shares of the company’s stock, valued at approximately $645,901.02. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Virginia Ruth Sanzone sold 2,050 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares in the company, valued at approximately $645,901.02. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $16,320,691.72. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,552 shares of company stock valued at $6,679,322 over the last 90 days. Company insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.